Create a free account to keep browsing
It takes 30 seconds. You can open three notice pages a day without an account; a free account opens every notice, and lists the ones in your NAICS codes.
NOI - DNA Sequencing of Bone Marrow Failure Syndro
National Institutes of Health · NATIONAL INSTITUTES OF HEALTH OLAO
Respond by: Nov 2, 2026, 9:00 AM UTC−53 days left
From SAM.gov's public data file generated Oct 29, 2026, 3:30 AM UTC; newest notice posted Oct 29, 2026; loaded into FedSub Oct 29, 2026, 5:46 AM UTC
Notice facts
Source: SAM.gov Contract Opportunities public data file
- Solicitation number
- 75N98027Q00027
- Notice type
- Combined synopsis/solicitation
- Posted
- Oct 22, 2026
- Response date
- Respond by Nov 2, 2026, 9:00 AM UTC−5
- Set-aside
- None stated
- NAICS code
- 325413 In-Vitro Diagnostic Substance Manufacturing
- Product or service code
- 6550
- Place of performance
- Not stated
- Contracting office
- NATIONAL INSTITUTES OF HEALTH OLAO (75N980)BETHESDA, MD 20892
- Agency
- Department of Health and Human Services · National Institutes of Health
Past prime awardees
Source: Award history, not a list of bidders on this notice
Past prime awardees · award history, not a list of bidders on this notice
1 company held prime contracts from this office under NAICS 325413.
- OXFORD NANOPORE TECHNOLOGIES, INC. · No first-tier subawards reported in FedSub's data
Description
Source: SAM.gov Contract Opportunities public data file
(i) This is a combined synopsis/solicitation for commercial items prepared in accordance with the format in FAR Subpart 12.6, as supplemented with additional information included in this notice. This announcement constitutes the only solicitation; proposals are being requested, and a separate written solicitation will not be issued. (ii) The solicitation number is 75N98027Q00027. This solicitation is issued as a Notice of Intent (NOI) for a non-competitive combined synopsis/solicitation to award a contract or purchase order without providing for full and open competition (including brand-name, if applicable). This acquisition is conducted under the authority of FAR 12.603, Streamlined Solicitation for Commercial Products or Commercial Services, and is not expected to exceed the simplified acquisition threshold. Additional authority includes 41 U.S.C. 1901 and FAR 6.302-3(a)(2)(ii). The National Institutes of Health (NIH), Office of the Director, Office of Acquisitions, intends to negotiate and award a firm-fixed-price purchase order on a non-competitive basis to Integrated DNA Technologies, Inc. (IDT), 1710 Commercial Park, Coralville, IA 52241, for custom-designed ArcherDX VariantPlex Next-Generation Sequencing (NGS) target-enrichment library preparation kits. Integrated DNA Technologies, Inc. is the sole owner, manufacturer, and distributor of the proprietary ArcherDX VariantPlex Anchored Multiplex PCR (AMP) chemistry, which has been utilized by the NHLBI Hematology Branch since 2019 to perform error-correcting sequencing (ECS) and is required to maintain scientific continuity, prevent technical batch effects across longitudinal patient cohorts, and ensure compatibility with the laboratory¿s established Archer Analysis bioinformatics pipeline. All responsible sources may submit a capability statement, proposal, or quotation, which shall be considered by the agency. (iii) The solicitation document and incorporated provisions and clauses are those in effect through…
Versions on SAM.gov
Source: SAM.gov Contract Opportunities public data file
Posted Oct 22, 2026Combined synopsis/solicitationCurrent version
Respond by Nov 2, 2026, 9:00 AM UTC−5
This version on SAM.gov (opens SAM.gov in a new tab)